← All trials
NCT04572685
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 22, 2020
- Primary completion
- Jun 26, 2020
- Completion date
- Aug 20, 2020
- First posted
- Oct 1, 2020
- Last posted
- Nov 9, 2020
- Enrollment
- 36
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Luye PharmaLead sponsor
- National Cancer Institute (NCI)Collaborator
- Luye PharmaStudy chair
- Evolution Research GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.